Preskoči na sadržaj
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Napredno
  • Efficacy and safety of MPC-786...
  • Citiraj ovo
  • Pošalji tekstualnu poruku
  • Pošalji ovo e-mailom
  • Ispiši
  • Izvezi zapis
    • Izvezi u RefWorks
    • Izvezi u EndNoteWeb
    • Izvezi u EndNote
  • Stalna poveznica
Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study

Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study

Bibliografski detalji
Glavni autori: Black, S, Wilcock, G, Haworth, J, Hendrix, S, Zavitz, K, Christensen, D, Binger, M, Bass, S, Laughlin, M, Swabb, E
Format: Conference item
Izdano: 2006
  • Primjerci
  • Opis
  • Slični predmeti
  • Prikaz za djelatnike knjižnice

Slični predmeti

  • Efficacy and safety of MPC-7869 (R-flurbiprofen), a Selective AB42-Lowering Agent, in Alzheimer's disease (AD): Results of a 12-month phase 2 trial and 1-year follow-on study.
    od: Laughlin, M, i dr.
    Izdano: (2006)
  • Flurizan, (MPC-7869, (R)-flurbiprofen) a selective A beta-42 lowering agent in patients with mild to moderate Alzheimer's disease: A randomised, placebo-controlled, double blind trial
    od: Wilcock, G, i dr.
    Izdano: (2005)
  • Efficacy and safety of tarenflurbil, a selective a beta 42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment
    od: Black, S, i dr.
    Izdano: (2008)
  • Efficacy and safety of tarenflurbil (flurizan), a selective Abeta42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment
    od: Wilcock, G, i dr.
    Izdano: (2007)
  • Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    od: Wilcock, G, i dr.
    Izdano: (2008)

Opcije pretrage

  • Povijest pretrage
  • Napredna pretraga

Pronađi više

  • Pregledaj katalog
  • Pregledaj abecednim redom
  • Istraži kanale
  • Rezervacije tečajeva
  • Novi predmeti

Trebaš pomoć?

  • Savjeti za pretragu
  • Upitaj knjižničara
  • Često postavljena pitanja